Regeneron Pharmaceuticals, Inc. (REGN): who owns it and who trades it
As of Nov 16, 2026, REGN insiders reported 134 open-market sales worth $57.9M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was George L Sing (Director), with $20.4M. 10 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Regeneron Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns REGN
1,330 funds and institutions reported REGN shares worth $57.7B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $5.7B.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 9.11M | – | $5.7B | +2% |
| Vanguard Capital Management LLC | 6.63M | – | $4.1B | -0% |
| Dodge & Cox | 4.87M | – | $3B | +9% |
| State Street Corp | 4.83M | – | $3B | +4% |
| Invesco Ltd. | 3.94M | – | $2.5B | +129% |
| JPMorgan Chase & Co | 3.77M | – | $2.4B | – |
| Vanguard Portfolio Management LLC | 3.18M | – | $2B | +85% |
| Franklin Resources Inc | 2.77M | – | $1.7B | +2% |
| Geode Capital Management, LLC | 2.63M | – | $1.6B | +1% |
| Nuveen, LLC | 2.02M | – | $1.3B | -2% |
| Loomis Sayles & Co L P | 1.86M | – | $1.2B | -3% |
| T. Rowe Price Associates | 1.53M | – | $954M | -30% |
| Morgan Stanley | 1.40M | – | $872M | +6% |
| Bank of America Corp | 1.29M | – | $805M | +9% |
| Wellington Management Group LLP | 1.27M | – | $792M | -31% |
| Norges Bank | 1.17M | – | $731M | – |
| Goldman Sachs Group Inc | 1.16M | – | $725M | -11% |
| AQR Capital Management LLC | 1.13M | – | $702M | -9% |
| Amundi | 1.01M | – | $632M | +0% |
| Northern Trust Corp | 916,467 | – | $571M | -3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, REGN insiders reported $0 of open-market purchases and $57.9M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 439 | $939.57 | $412K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 575 | $940.46 | $541K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 982 | $941.58 | $925K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 1,215 | $942.31 | $1.1M | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 529 | $943.53 | $499K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 108 | $944.22 | $102K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 35 | $945.61 | $33.1K | Form 4 |
| Nov 4, 2026 | Jason Pitofsky | Vice president | Sale | 179 | $950.76 | $170K | Form 4 |
| Nov 3, 2026 | Huda Y Zoghbi | Director | Sale | 6,939 | $970.42 | $6.7M | Form 4 |
| Nov 3, 2026 | Huda Y Zoghbi | Director | Sale | 500 | $971.06 | $486K | Form 4 |
| Nov 2, 2026 | Joseph J Larosa | Vice president | Sale | 3,939 | $965.41 | $3.8M | Form 4 |
| Nov 2, 2026 | Joseph J Larosa | Vice president | Sale | 527 | $966.11 | $509K | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 218 | $966.74 | $211K | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 772 | $967.38 | $747K | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 2,499 | $968.58 | $2.4M | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 3,203 | $969.50 | $3.1M | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 937 | $970.51 | $909K | Form 4 |
| Nov 2, 2026 | Christine A Poon | Director | Sale | 201 | $971.31 | $195K | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 1,224 | $960.57 | $1.2M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 540 | $961.85 | $519K | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 2,522 | $962.61 | $2.4M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 4,338 | $963.47 | $4.2M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 2,670 | $964.57 | $2.6M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 7,073 | $965.38 | $6.8M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 1,522 | $966.27 | $1.5M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 1,040 | $967.07 | $1M | Form 4 |
| Nov 2, 2026 | George L Sing | Director | Sale | 200 | $970.18 | $194K | Form 4 |
| Oct 30, 2026 | Michael S Brown | Director | Sale plan | 1,929 | $875.00 | $1.7M | Form 4 |
| Oct 30, 2026 | Kathryn Guarini | Director | Sale plan | 400 | $900.00 | $360K | Form 4 |
| Oct 30, 2026 | Marion McCourt | Vice president | Sale plan | 1,132 | $869.43 | $984K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 6 | $753.76 | $4.5K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 35 | $755.91 | $26.5K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 16 | $757.68 | $12.1K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 24 | $758.16 | $18.2K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 14 | $759.96 | $10.6K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 74 | $760.65 | $56.3K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 27 | $761.36 | $20.6K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 55 | $762.57 | $41.9K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 25 | $763.76 | $19.1K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 219 | $764.40 | $167K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 271 | $765.39 | $207K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 279 | $766.47 | $214K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 192 | $767.39 | $147K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 105 | $768.33 | $80.7K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 127 | $769.30 | $97.7K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 12 | $770.20 | $9.2K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 283 | $771.56 | $218K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 211 | $772.56 | $163K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 224 | $773.40 | $173K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 121 | $774.48 | $93.7K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 376 | $775.46 | $292K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 66 | $776.31 | $51.2K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 38 | $777.76 | $29.6K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 454 | $778.64 | $354K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 380 | $779.59 | $296K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 463 | $780.63 | $361K | Form 4 |
| Oct 14, 2026 | Andrew J Murphy | Co-Chief Scientific Offi | Sale plan | 50 | $781.47 | $39.1K | Form 4 |
| Sep 3, 2026 | Marion McCourt | Vice president | Sale plan | 1,131 | $857.39 | $970K | Form 4 |
| Sep 2, 2026 | Marion McCourt | Vice president | Sale plan | 1,215 | $850.00 | $1M | Form 4 |
| Sep 2, 2026 | Kathryn Guarini | Director | Sale plan | 400 | $850.00 | $340K | Form 4 |
| Aug 10, 2026 | Kathryn Guarini | Director | Sale plan | 400 | $800.00 | $320K | Form 4 |
| Aug 10, 2026 | Huda Y Zoghbi | Director | Sale plan | 800 | $800.00 | $640K | Form 4 |
| Jul 2, 2026 | Arthur F Ryan | Director | Sale plan | 200 | $650.15 | $130K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $710.87 | $1.4K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 5 | $711.49 | $3.6K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 1 | $712.09 | $712 | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $714.13 | $1.4K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 4 | $707.40 | $2.8K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 6 | $709.45 | $4.3K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 7 | $706.74 | $4.9K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 14 | $705.56 | $9.9K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 15 | $704.28 | $10.6K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 24 | $703.46 | $16.9K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 5 | $701.76 | $3.5K | Form 4 |
| May 1, 2026 | Arthur F Ryan | Director | Sale plan | 15 | $702.46 | $10.5K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 13 | $776.62 | $10.1K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 9 | $777.42 | $7K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 4 | $778.24 | $3.1K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 40 | $779.71 | $31.2K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 14 | $775.58 | $10.9K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 8 | $773.59 | $6.2K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 3 | $772.76 | $2.3K | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 1 | $771.32 | $771 | Form 4 |
| Apr 1, 2026 | Arthur F Ryan | Director | Sale plan | 8 | $774.58 | $6.2K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 20 | $788.96 | $15.8K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $787.34 | $1.6K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 7 | $786.61 | $5.5K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 11 | $785.48 | $8.6K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $781.21 | $1.6K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 10 | $783.62 | $7.8K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $782.62 | $1.6K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 7 | $777.46 | $5.4K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 2 | $778.30 | $1.6K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 5 | $779.69 | $3.9K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 3 | $780.69 | $2.3K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 20 | $789.28 | $15.8K | Form 4 |
| Mar 2, 2026 | Arthur F Ryan | Director | Sale plan | 9 | $784.48 | $7.1K | Form 4 |
| Feb 19, 2026 | Huda Y Zoghbi | Director | Sale plan | 4 | $790.00 | $3.2K | Form 4 |
| Feb 19, 2026 | Huda Y Zoghbi | Director | Sale plan | 160 | $784.45 | $126K | Form 4 |
| Feb 19, 2026 | Huda Y Zoghbi | Director | Sale plan | 56 | $785.61 | $44K | Form 4 |
Latest 100 of 134 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George L Sing | Director | – | $20.4M | Nov 2, 2026 |
| Huda Y Zoghbi | Director | – | $9.1M | Nov 3, 2026 |
| Christine A Poon | Director | – | $7.6M | Nov 2, 2026 |
| Jason Pitofsky | SVP Controller | – | $5.4M | Nov 4, 2026 |
| Joseph J Larosa | EVP General Counsel and Secret | – | $4.3M | Nov 2, 2026 |
| Andrew J Murphy | Co-Chief Scientific Officer | – | $3.2M | Oct 14, 2026 |
| Marion McCourt | EVP Commercial | – | $3M | Oct 30, 2026 |
| Bonnie L Bassler | Director | – | $1.8M | Jan 7, 2026 |
| Michael S Brown | Director | – | $1.7M | Oct 30, 2026 |
| Kathryn Guarini | Director | – | $1M | Oct 30, 2026 |
| Arthur F Ryan | Director | – | $435K | Jul 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
REGN short interest
2.22M REGN shares are sold short. Over the last 12 reports the number of shares short went down 20%.
As of Oct 30, 2026, 2.22M REGN shares were sold short, up 3.8% from the report before. At the average daily volume of 810,850 shares, buying them all back would take about 2.7 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.22M | – | +4% | 810,850 | 2.7 |
| Oct 15, 2026 | 2.13M | – | -1% | 670,714 | 3.2 |
| Sep 30, 2026 | 2.15M | – | -15% | 863,842 | 2.5 |
| Sep 15, 2026 | 2.53M | – | -1% | 571,271 | 4.4 |
| Aug 31, 2026 | 2.55M | – | +7% | 662,864 | 3.9 |
| Aug 14, 2026 | 2.40M | – | -29% | 760,654 | 3.1 |
| Jul 31, 2026 | 3.39M | – | -3% | 858,662 | 3.9 |
| Jul 15, 2026 | 3.50M | – | +0% | 741,224 | 4.7 |
| Jun 30, 2026 | 3.49M | – | +6% | 1.20M | 2.9 |
| Jun 15, 2026 | 3.30M | – | +10% | 968,690 | 3.4 |
| May 29, 2026 | 3.00M | – | +8% | 1.53M | 2.0 |
| May 15, 2026 | 2.78M | – | -15% | 764,041 | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded REGN
Since Nov 17, 2024, 8 members of Congress reported 5 purchases and 9 sales of REGN. The latest was a sale by Gilbert Ray Cisneros, Jr. on May 15, 2026, reported Jun 8, 2026.
Purchases 5Sales 9
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 15, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Jun 8, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Feb 12, 2026 | Julia Letlow (R-LA) | Purchase | $1K–$15K | Self | Mar 12, 2026 | Report |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Jun 9, 2025 | Report |
| Apr 10, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Self | May 24, 2025 | Report |
| Apr 10, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Spouse | May 24, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | May 8, 2025 | Report |
| Apr 7, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | May 8, 2025 | Report |
| Apr 1, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | May 14, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | Mar 27, 2025 | Report |
| Feb 12, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Mar 12, 2025 | Report |
| Jan 24, 2025 | Josh Gottheimer (D-NJ) | Sale | $1K–$15K | Joint | Feb 10, 2025 | Report |
| Jan 15, 2025 | Julie Johnson (D-TX) | Purchase | $1K–$15K | Joint | Feb 12, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Regeneron Pharmaceuticals company events
Regeneron Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 30, 2026.
- Oct 30, 2026ResultsReleased financial results. Filing
- Oct 6, 2026AgreementRegeneron Pharmaceuticals, Inc., a New York corporation, Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France, and Sanofi, a société anonyme organized under the laws of France, entered into the Sixth Amendment to the Amended and Restated License and… Filing
- Sep 30, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jul 6, 2026ResultsReleased financial results. Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Apr 8, 2026ResultsReleased financial results. Filing
- Jan 30, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Regeneron Pharmaceuticals financials
Famous investors that hold REGN
10 of the 50 well-known investors we track reported holding REGN in their latest 13F filing. The largest position is Ken Griffin's, worth $267M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 352,728 | $267M | 0.1% | +512% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 272,218 | $206M | 0.3% | +84% |
| Israel Englander · Millennium Management | Q3 2026 | 147,538 | $112M | 0.1% | -11% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 124,380 | $94.3M | 0.2% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 105,934 | $80.3M | 0.3% | +106% |
| Jeremy Grantham · GMO | Q3 2026 | 71,076 | $53.9M | 0.1% | -4% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 37,604 | $28.5M | 0.1% | New |
| Lee Ainslie · Maverick Capital | Q3 2026 | 1,824 | $1.4M | 0.0% | New |
| Richard Pzena · Pzena Investment Management | Q3 2026 | 409 | $310K | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 347 | $264K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Regeneron Pharmaceuticals, Inc. (REGN) stock
Who owns the most REGN stock?
The largest reported owner of Regeneron Pharmaceuticals, Inc. (REGN) is BlackRock, Inc.. In total, 1,330 funds and institutions reported holding REGN at the end of Q2 2026. See the largest owners.
Are REGN insiders buying or selling?
In the last 12 months, REGN insiders reported no open-market purchases and 134 sales worth $57.9M. The latest trade was on Nov 4, 2026. See every trade.
What is the short interest in REGN?
As of Oct 30, 2026, 2.22M REGN shares were sold short, up 3.8% from the report before. At the average daily volume of 810,850 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.
Have members of Congress traded REGN?
Yes. 8 members of Congress reported 5 purchases and 9 sales of REGN since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.
Which famous investors hold REGN?
10 of the 50 well-known investors we track reported REGN in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $267M. See all holders.
Executive pay
Regeneron Pharmaceuticals's chief executive was paid a total of $7.3M for the year ended Dec 31, 2025, up 7% from $6.8M the year before. In the last 12 months, Regeneron Pharmaceuticals's executives and directors bought no stock on the open market and sold $57.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.